To ensure the safety and quality of medicinal products, Taiwan has fully implemented the international PIC/S GMP standards, and the pharmaceutical manufacturers could apply for GMP certificates from the Taiwan Food and Drug Administration (TFDA) after inspection and found in compliance with PIC/S GMP.
As technology advances and markets globalize, TFDA is committed to digital transformation, aligning with international digital trends. Start-ing from July 31, 2024 beside hard copy, the TFDA also began issu-ing digital GMP certificates, which include a digital signature. These digital certificates are encrypted using a digital signature that meets the global Adobe Approved Trust List and Taiwan’s Electronic Sig-natures Act, can quickly verify via scanning QR code or uploading PDF file to a verification platform, and more than a thousand times verifications have been conducted since plateform launched, clearly demonstrating that the global competitiveness of Taiwan’s pharma-ceutical manufactures has been effectively boosted.
The TFDA emphasizes its commitment to ensuring that the public has access to pharmaceutical products of equivalent to those found in ad-vanced contries, and enhancing the international competitiveness of Taiwan's pharmaceutical manufacturers. TFDA will continue to en-hance the management of pharmaceutical manufacturers, align with the policy of digital governance, and strive to achieve the goal of guaranteeing the safety and quality of pharmaceuticals for the World.